Ace Therapeutics recently launched in vivo efficacy testing services for IBD drug candidates. Ace Therapeutics, a preclinical ...

Researchers at the University of Plymouth are leading an innovative initiative to advance the study of meningiomas in NF2-related schwannomatosis (NF2-SWN). Meningiomas, often linked to the loss of ...

Experts predict a test measuring p-tau217 in blood plasma may become a standard screening tool for Alzheimer’s disease in ...

A new precision medicine initiative is doing a bit of pharmaceutical matchmaking to see if preclinical evidence for cancer drug combos holds up beyond the lab. The National Institutes of Health (NIH) ...

'OPENING THE DOOR': FDA's Joseph Contrera claims the new testing guidelines will encourage innovation. The Food and Drug Administration (FDA) is considering a plan to revise a 25-year staple of ...

The Baylor/Rice Genome Editing Testing Center (GETC) offers researchers in vivo evaluation of genome editing activity, biodistribution and efficacy in mouse models as a fee-for-service. Our center ...

Approximately 75% of anticancer drugs must be tested against paediatric cancer. Drug developers can now use a database of patient-derived tumour models to screen their products for paediatric cancer ...

Plasma phosphorylated (p)-tau217 testing can help identify preclinical Alzheimer's disease (AD), which could aid clinical trial recruitment. Recruiting preclinical AD participants for clinical ...

To test new stroke treatments, a research team from the Keck School of Medicine of USC develops a more rigorous system for conducting preclinical research that could lead to more successful clinical ...

Researchers at New York University Abu Dhabi (NYUAD) have developed Spheromatrix, a simple and low-cost technology that enables tumor models to be grown, frozen, and stored for future use in cancer ...

Carlin is a vice president at Pathway Policy Group and a veterinarian. Paragas is the CEO and founder of DVLP Medicines and a virologist. The Food and Drug Administration’s recent decision to phase ...

95% of clinical trials fail because animal testing is no substitute for human biology - Vivodyne’s robotics platform grows thousands of human tissues daily, directly tackling the biological gap behind ...